Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | APEX1 | P27695 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | LIPE | Q05469 | 5/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.44 |
| ▸ | RHEB | Q15382 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15096443 | 0.84 | RAB9A (0.45) | SMN1; SMN2LMNACYP2C9TSHRAPEX1 | |
| SCHEMBL22229496 | 0.82 | PPARG (0.42) | SMN1; SMN2LMNACYP2C9TSHRAPEX1 | |
| SCHEMBL876550 | 0.81 | RAB9A (0.60) | SMN1; SMN2LMNARAB9AKMT2ASCN9A | |
| SCHEMBL366394 | 0.78 | NPC1 (0.43) | SMN1; SMN2LMNACYP2C9TSHRAPEX1 | |
| SCHEMBL30127171 | 0.76 | SMN1; SMN2 (0.56) | SMN1; SMN2LMNACYP2C9TSHRAPEX1 | |
| SCHEMBL4006028 | 0.75 | LTA4H (0.55) | TSHRLTA4HTTRRHEB | |
| SCHEMBL17069359 | 0.73 | RORC (0.42) | SMN1; SMN2LMNACYP2C9TSHRAPEX1 | |
| SCHEMBL21191145 | 0.73 | SMN1; SMN2 (0.45) | SMN1; SMN2LMNACYP2C9TSHRAPEX1 | |
| SCHEMBL7943182 | 0.73 | SMN1; SMN2 (0.73) | SMN1; SMN2LMNALIPERAB9AMEN1 | |
| SCHEMBL4166189 | 0.72 | HPGD (0.44) | TSHRNR1H2NR1H3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163535-A1 | Substituted Heteroarylalkanoic Acids | THE INSTITUES FOR PHARMACEUTICAL DISCOVERY, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| EP-1444228-B1 | SUBSTITUTED HETEROARYLALKANOIC ACIDS AND THEIR USE AS ALDOSE REDUCTASE INHIBITORS | INST FOR PHARM DISCOVERY INC (US) | 2008-05-21 | — | — | EP | disclosed |
| US-7361671-B2 | Substituted heteroarylalkanoic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-20030166668-A1 | Substituted heteroarylalkanoic acids | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, INC. A CORPORATION OF THE STATE OF DELAWARE | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163535-A1 | Substituted Heteroarylalkanoic Acids | GPR119, LIPA, LIPC | SMN1; SMN2 4596/4885LMNA 3184/4885CYP2C9 552/4885 |
| US-20030166668-A1 | Substituted heteroarylalkanoic acids | GPR119, LIPA, DDC | SMN1; SMN2 4572/4885LMNA 3008/4885CYP2C9 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.